AAAAAA
Results:
1-15
|
Results: 15
Authors:
Judson, I
Radford, JA
Harris, M
Blay, JY
van Hoesel, Q
le Cesne, A
van Oosterom, AT
Clemons, MJ
Kamby, C
Hermans, C
Whittaker, J
di Paola, ED
Verweij, J
Nielsen, S
Citation: I. Judson et al., Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL (R)/CAELYX (R)) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group, EUR J CANC, 37(7), 2001, pp. 870-877
Authors:
Verweij, J
Judson, I
van Oosterom, A
Citation: J. Verweij et al., STI571: a magic bullet?, EUR J CANC, 37(15), 2001, pp. 1816-1819
Authors:
Ng, C
Stebbing, J
Judson, I
Citation: C. Ng et al., Cardiac metastasis from a myxoid liposarcoma, CL ONCOL-UK, 13(5), 2001, pp. 384-385
Authors:
van Oosterom, AT
Judson, I
Verweij, J
Stroobants, S
di Paola, ED
Dimitrijevic, S
Martens, M
Webb, A
Sciot, R
Van Glabbeke, M
Silberman, S
Nielsen, OS
Citation: At. Van Oosterom et al., Safety and efficacy of imatinib (ST1571) in metastatic gastrointestinal stromal tumours: a phase I study, LANCET, 358(9291), 2001, pp. 1421-1423
Authors:
Nielsen, OS
Judson, I
van Hoesel, Q
le Cesne, A
Keizer, HJ
Blay, JY
van Oosterom, A
Radford, JA
Svancarova, L
Krzemienlecki, K
Hermans, C
van Glabbeke, M
Oosterhuis, JW
Verweij, J
Citation: Os. Nielsen et al., Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group, EUR J CANC, 36(1), 2000, pp. 61-67
Authors:
Clarke, PA
Hostein, I
Banerji, U
Di Stefano, F
Maloney, A
Walton, M
Judson, I
Workman, P
Citation: Pa. Clarke et al., Gene expression profiling of human colon cancer cells following inhibitionof signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of hsp90 molecular chaperone, ONCOGENE, 19(36), 2000, pp. 4125-4133
Authors:
Briasoulis, E
Judson, I
Pavlidis, N
Beale, P
Wanders, J
Groot, Y
Veerman, G
Schuessler, M
Niebch, G
Siamopoulos, K
Tzamakou, E
Rammou, D
Wolf, L
Walker, R
Hanauske, A
Citation: E. Briasoulis et al., Phase I trial of 6-hour infusion of glufosfamide, a new alkylating agent with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters: A study of the European Organization for Researchand Treatment of Cancer Early Clinical Studies Group, J CL ONCOL, 18(20), 2000, pp. 3535-3544
Authors:
Le Cesne, A
Judson, I
Crowther, D
Rodenhuis, S
Keizer, HJ
Van Hoesel, Q
Blay, JY
Frisch, J
Van Glabbeke, M
Hermans, C
Van Oosterom, A
Tursz, T
Verweij, J
Citation: A. Le Cesne et al., Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group, J CL ONCOL, 18(14), 2000, pp. 2676-2684
Authors:
Judson, I
Kelland, LR
Citation: I. Judson et Lr. Kelland, New developments and approaches in the platinum arena, DRUGS, 59, 2000, pp. 29-36
Authors:
Kelland, LR
Giaccone, G
Judson, I
Citation: Lr. Kelland et al., Questions and answers, DRUGS, 59, 2000, pp. 37-38
Authors:
Woll, PJ
Judson, I
Lee, SM
Rodenhuis, S
Nielsen, OS
Buesa, JM
Lorigan, PC
Leyvraz, S
Hermans, C
van Glabbeke, M
Verweij, J
Citation: Pj. Woll et al., Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC soft tissue and bone sarcoma group, EUR J CANC, 35(3), 1999, pp. 410-412
Authors:
Blay, JY
Judson, I
Rodenhuis, S
Hermans, C
Smith, M
van Glabbeke, M
Verweij, J
Citation: Jy. Blay et al., Phase II study of raltitrexed ('Tomudex') for patients with advanced soft tissue sarcomas refractory to doxorubicin-containing regimens, ANTI-CANC D, 10(10), 1999, pp. 873-877
Authors:
Beale, P
Judson, I
Moore, S
Statkevich, P
Marco, A
Cutler, DL
Reidenberg, P
Brada, M
Citation: P. Beale et al., Effect of gastric pH on the relative oral bioavailability and pharmacokinetics of temozolomide, CANC CHEMOT, 44(5), 1999, pp. 389-394
Authors:
Brada, M
Judson, I
Beale, P
Moore, S
Reidenberg, P
Statkevich, P
Dugan, M
Batra, V
Cutler, D
Citation: M. Brada et al., Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies, BR J CANC, 81(6), 1999, pp. 1022-1030
Authors:
Twelves, CJ
Gardner, C
Flavin, A
Sludden, J
Dennis, I
de Bono, J
Beale, P
Vasey, P
Hutchison, C
Macham, MA
Rodriguez, A
Judson, I
Bleehen, NM
Citation: Cj. Twelves et al., Phase I and pharmacokinetic study of DACA (XR5000): a novel inhibitor of topoisomerase I and II, BR J CANC, 80(11), 1999, pp. 1786-1791
Risultati:
1-15
|